Tscan therapeutics announces upcoming presentations at the 2024 american society of clinical oncology annual meeting

Waltham, mass., april 24, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 american society of clinical oncology (asco) annual meeting being held may 31 – june 4 in chicago, il as well as virtually.
TCRX Ratings Summary
TCRX Quant Ranking